The Correlation Between the Treatment Efficacy and the Sympathetic Activity in Men With Lower Urinary Tract Symptoms

by

Hyun Ik Jang

Major in Medicine
Department of Medical Sciences
The Graduate School, Ajou University
The Correlation Between the Treatment Efficacy and the Sympathetic Activity in Men With Lower Urinary Tract Symptoms

by
Hyun Ik Jang

A Dissertation Submitted to The Graduate School of Ajou University in Partial Fulfillment of the Requirements for the Degree of Master of Medicine

Supervised by
Jong Bo Choi, M.D., Ph.D.

Major in Medicine
Department of Medical Sciences
The Graduate School, Ajou University
February, 2015
This certifies that the dissertation of Hyun Ik Jang is approved.

SUPERVISORY COMMITTEE

__________________________
Jong Bo Choi

__________________________
Hyun Su Ahn

__________________________
Sun Il Kim

The Graduate School, Ajou University
December, 19th, 2014
ABSTRACT

The Correlation Between the Treatment Efficacy and the Sympathetic Activity in Men With Lower Urinary Tract Symptoms

Purpose: In this study, we examined the difference in the treatment efficacy depending on the sympathetic activity in men with lower urinary tract symptoms (LUTS).

Methods: In the current single-center, retrospective study, we evaluated a total of 66 male patients aged 40–70 years of age, presenting with LUTS, whose International Prostate Symptom Score (IPSS) exceeded 8 points. They had a past 3-month history of taking alfuzosin XL, and their heart rate variability (HRV) was measured before and after the treatment. In addition, we also recruited 39 healthy volunteers who visited a health promotion center for a regular medical check-up. They were aged between 40 and 70 years and had an IPSS of <8 points. We divided the patients with LUTS into two groups: the groups A and B, based on a low frequency/high frequency (LF/HF) ratio of 1.7, which was the mean value of the LF/HF ratio in the healthy volunteers. After a 3-month treatment with alfuzosin XL, we compared treatment outcomes, based on the IPSS and peak urine flow rate, between the two groups.

Results: A 3-month treatment with alfuzosin XL, comprising the measurement of the HRV, was performed for the 23 patients of the group A (23/38) and 17 of the group B (17/28). After a 3-month treatment with alfuzosin XL, total IPSS and IPSS questionnaire 2 and 5 were significantly lower in the group A as compared with the group B. But this was not seen in the group B. Furthermore, there were no significant differences in other parameters,
such as maximal flow rate and IPSS storage subscore, between the two groups.

**Conclusions:** Our results indicate that the treatment efficacy was lower in patients with sympathetic hyperactivity as compared with those with sympathetic hypoactivity. Thus, our results will provide a basis for further studies to clarify causes of LUTS in a clinical setting.

Keywords : Autonomic nervous system; Heart rate; Lower urinary tract symptoms
# TABLE OF CONTENTS

ABSTRACT ........................................................................................................................................... i
TABLE OF CONTENTS ........................................................................................................................ iii
LIST OF TABLES .................................................................................................................................. iv
I . INTRODUCTION .......................................................................................................................... 1
II . MATERIALS AND METHODS ...................................................................................................... 2
III . RESULTS ..................................................................................................................................... 4
IV . DISCUSSION ............................................................................................................................. 9
V . CONCLUSION ........................................................................................................................... 12
REFERENCES .................................................................................................................................... 12
국문요약 .......................................................................................................................................... 14
LIST OF TABLES

Table 1. Clinical characteristics of 36 healthy volunteers ........................................ 5

Table 2. Patients characteristics and change of IPSS parameter and uroflowmetry in two subgroups of patients with lower urinary tract symptoms depending on the sympathetic activity ........................................ 6

Table 3. Difference of the IPSS and Qmax after a 3-month treatment .......................... 7
I. INTRODUCTION

Lower urinary tract symptoms (LUTS) in men is a common symptom whose mechanism and etiology remain unclear (McVary KT et al, 2005). It may be such a bothersome condition as to lead to the anxiety and even morbidity (Ushijima S et al, 2006). Moreover, due to the involvement of the prostate, LUTS shows different characteristics between men and women; voiding symptoms are more common in men than women. Idiopathic overactive bladder (OAB) is common in both sexes. Most patients with idiopathic OAB suffer from frequency, urgency and nocturia. To date, many studies have mainly examined the involvement of muscarinic receptors and the nervous system innervating the bladder in the pathogenesis of OAB. Moreover, it is widely known that the autonomic nervous system (ANS) is involved in the regulation of the micturition cycle. That is, there are several reports about the correlation between the activity of the ANS and the LUTS (Choi JB et al, 2010; Hubeaux K et al, 2011; Liao WC et al, 2010; Ben-Dror I et al, 2012). It is presumed that the central sympathetic overactivity might be associated with the LUTS in patients with benign prostatic hyperplasia (BPH); it is associated with metabolic syndrome in men (McVary KT et al, 2005; Kibry MG et al, 2010).

The heart rate variability (HRV) can be used to assess the activity of the ANS. It is a quantitative, qualitative and noninvasive indicator of the systemic autonomic function. Autonomic dysfunction may be a causative factor for LUTS because the lower urinary tract is innervated and controlled by the ANS.

To date, few studies have been conducted to examine the correlation between the activity of the ANS and the LUTS in men, if any, and have suggested not only that it
contributes to the pathophysiology of the OAB but also that it may affect the treatment effects in male patients with LUTS.

Given the above background, we conducted this study to examine the difference in the treatment efficacy depending on the sympathetic activity in men with LUTS.

## II. MATERIALS AND METHODS

In the current single-center, retrospective study, we evaluated a total of 66 male patients aged 40.70 years of age, presenting with LUTS, whose International Prostate Symptom Score (IPSS) exceeded 8 points. This study was initiated with approval of the Institutional Review Board of Ajou University College of Medicine (MED-MDB-12-273). They had a past 3-month history of taking alfuzosin XL, and their HRV was measured before and after the treatment. Thus, they were assigned to the patient group (n=66).

In addition, we also recruited 39 healthy volunteers who visited a health promotion center for a regular medical check-up. They were aged between 40 and 70 years and had an IPSS of <8 points. They had no underlying diseases that may affect the ANS, such as diabetes, cardiovascular disease, neurologic disturbance or any malignancies. In addition, they had no past history of surgery or pelvic trauma or that of taking medications that may affect the ANS. We excluded those who had a history of pelvic surgery or urinary retention, postvoiding residual urine of >100 and serum PSA of >10 ng/mL.

We informed the patients with a PSA level of >4 ng/mL of the necessity to measure the PSA levels or to undergo prostate biopsy. We divided the patients with LUTS into two groups: the groups A and B, based on a low frequency/high frequency (LF/HF) ratio of 1.7,
which was the mean value of the LF/HF ratio in the healthy volunteers (Table 1). After a 3-month treatment with alfuzosin XL, we compared treatment outcomes, based on the IPSS and peak urine flow rate, between the two groups.

The HRV was measured using the SA-3000p (Medicore, Seoul, Korea). At baseline, all the subjects received a bladder scan; the bladder contained at least 100 mL of urine. After a 30-minute resting, each subject underwent electrocardiographic signal recording for five minutes in a sitting position. With the subjects breathing normally, we calculated the mean heart rate and standard deviation of the N-N interval (SDNN) and the square root of the mean squared differences in successive N-N intervals (RMSSD) using time domain analysis. SDNN reflects all the cyclic components that are responsible for variability in the recording period and RMSSD represents the parasympathetic activity. But we did not compare the SDNN and RMSSD because it has been believed that a 5-minute HRV test is not sufficient. The parameters of the frequency domain analysis are total power, very low frequency, LF and LF/HF ratio. The HF peak of the spectrum (0.15 to 0.40 Hz) represents parasympathetic activity, whereas the LF peak (0.04 to 0.15 Hz) represents sympathetic activity. Thus, the LF/HF ratio represents the ANS balance (sympathetic to parasympathetic activity).

Statistical analysis was performed using the IBM SPSS Statistics ver. 19.0 (IBM Co., Armonk, NY, USA). All data was expressed as mean±standard deviation. We also used the independent t-test to analyze differences in each parameter between the two groups. Furthermore, we performed the paired t-test to analyze the differences in each parameter between prior to and following the treatment. A P-value of <0.05 was considered statistically significant.
III. RESULTS

A. Baseline Characteristics of the Subjects

The mean age of healthy volunteers was 56.2 years. Their mean LF/HF ratio was 1.7 (Table 1). Based on a cutoff value of LF/HF ratio of 1.7, 38 (LF/HF ratio<1.7) and 28 patients with LUTS (LF/HF ratio ≥ 1.7) were assigned to the group A (n=38) and the group B (n=28), respectively. There were no significant differences in age, volume of the prostate, baseline maximal flow rate (Qmax) and IPSS total, IPSS voiding subscore (sum of IPSS questionnaire 1, 3, 5, and 6), and IPSS storage subscore (sum of IPSS questionnaire 2, 4, and 7) at baseline (Table 2).

B. Changes in IPSS and Qmax After a 3-Month Treatment With Alfuzosin XL

A 3-month treatment with alfuzosin XL, comprising the measurement of the HRV, was performed for the 23 patients of the group A (23/38) and 17 of the group B (17/28). The results of IPSS score and Qmax are shown in Table 3. After a 3-month treatment with alfuzosin XL, total IPSS and IPSS questionnaire 2 and 5 were significantly lower in the group A as compared with the group B. But this was not seen in the group B. Furthermore, there were no significant differences in other parameters, such as Qmax and IPSS storage subscore, between the two groups (Table 3).
Table 1. Clinical characteristics of 36 healthy volunteers

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>56.17 ± 6.63</td>
</tr>
<tr>
<td><strong>Heart rate variability</strong></td>
<td></td>
</tr>
<tr>
<td>LF (ms$^2$)</td>
<td>210.99 ± 264.05</td>
</tr>
<tr>
<td>HF (ms$^2$)</td>
<td>156.10 ± 166.11</td>
</tr>
<tr>
<td>LF/HF</td>
<td>1.70 ± 1.07</td>
</tr>
<tr>
<td><strong>International Prostate Symptom score</strong></td>
<td></td>
</tr>
<tr>
<td>Voiding subscore</td>
<td>3.03 ± 1.30</td>
</tr>
<tr>
<td>Storage subscore</td>
<td>1.64 ± 1.20</td>
</tr>
<tr>
<td>Total</td>
<td>4.69 ± 1.55</td>
</tr>
</tbody>
</table>

Values are presented as mean ± standard deviation.

LF, low frequency; HF, high frequency.
Table 2. The patient characteristics and change of IPSS parameter & uroflowmetry in two groups of LUTS patients by sympathetic activity

<table>
<thead>
<tr>
<th>Variable</th>
<th>Group A (n=38)</th>
<th>Group B (n=28)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>59.11 ± 9.92</td>
<td>57.89 ± 9.69</td>
<td>0.62</td>
</tr>
<tr>
<td>Volume of prostate</td>
<td>31.74 ± 10.29</td>
<td>31.17 ± 11.17</td>
<td>0.84</td>
</tr>
<tr>
<td>Baseline Qmax.</td>
<td>11.90 ± 6.84</td>
<td>11.92 ± 7.10</td>
<td>0.99</td>
</tr>
<tr>
<td>Baseline IPSS total</td>
<td>21.18 ± 7.81</td>
<td>18.00 ± 7.86</td>
<td>0.10</td>
</tr>
<tr>
<td>Baseline IPSS voiding</td>
<td>12.63 ± 5.28</td>
<td>10.89 ± 5.29</td>
<td>0.19</td>
</tr>
<tr>
<td>Baseline IPSS storage</td>
<td>7.50 ± 4.24</td>
<td>6.54 ± 3.62</td>
<td>0.34</td>
</tr>
</tbody>
</table>

Variables are presented as mean ± standard deviations.

Group A, patients with LF/HF below 1.7; Group B, patients with LF/HF 1.7 and over 1.7;
IPSS, International Prostate Symptom Score; Qmax, Peak uroflow; LF, low frequency; HF, high frequency; Qmax, maximal flow rate.
Table 3. Difference of the IPSS and Qmax after a 3-moth treatment

Group A (n=23)

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Baseline</th>
<th>After treatment</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Qmax (mL/sec)</td>
<td>11.59 ± 8.00</td>
<td>11.70 ± 6.01</td>
<td>0.946</td>
</tr>
<tr>
<td>IPSS total</td>
<td>20.93 ± 9.75</td>
<td>14.93 ± 5.18</td>
<td>0.006*</td>
</tr>
<tr>
<td>IPSS voiding</td>
<td>12.86 ± 5.22</td>
<td>10.50 ± 4.60</td>
<td>0.077</td>
</tr>
<tr>
<td>IPSS storage</td>
<td>6.79 ± 4.98</td>
<td>6.79 ± 2.58</td>
<td>1.000</td>
</tr>
<tr>
<td>IPSS No 1</td>
<td>3.73 ± 1.74</td>
<td>2.91 ± 1.97</td>
<td>0.381</td>
</tr>
<tr>
<td>IPSS No 2</td>
<td>2.55 ± 2.07</td>
<td>1.45 ± 1.51</td>
<td>0.038*</td>
</tr>
<tr>
<td>IPSS No 3</td>
<td>3.55 ± 1.69</td>
<td>2.10 ± 1.70</td>
<td>0.091</td>
</tr>
<tr>
<td>IPSS No 4</td>
<td>1.82 ± 2.18</td>
<td>0.82 ± 0.98</td>
<td>0.176</td>
</tr>
<tr>
<td>IPSS No 5</td>
<td>4.64 ± 0.67</td>
<td>2.73 ± 1.68</td>
<td>0.012*</td>
</tr>
<tr>
<td>IPSS No 6</td>
<td>2.45 ± 2.02</td>
<td>1.55 ± 1.86</td>
<td>0.346</td>
</tr>
<tr>
<td>IPSS No 7</td>
<td>2.64 ± 1.80</td>
<td>2.09 ± 1.38</td>
<td>0.441</td>
</tr>
<tr>
<td>IPSS No 8 (QoL)</td>
<td>3.93 ± 1.33</td>
<td>3.07 ± 1.35</td>
<td>0.061</td>
</tr>
</tbody>
</table>

Group B (n=17)

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Baseline</th>
<th>After treatment</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Qmax (mL/sec)</td>
<td>10.13 ± 4.25</td>
<td>12.91 ± 7.85</td>
<td>0.061</td>
</tr>
<tr>
<td>IPSS total</td>
<td>17.00 ± 9.75</td>
<td>17.11 ± 7.11</td>
<td>0.954</td>
</tr>
<tr>
<td>IPSS voiding</td>
<td>9.78 ± 5.78</td>
<td>10.56 ± 4.77</td>
<td>0.211</td>
</tr>
<tr>
<td>IPSS storage</td>
<td>6.78 ± 4.47</td>
<td>8.67 ± 3.64</td>
<td>0.170</td>
</tr>
<tr>
<td>IPSS No</td>
<td>Mean ± SD</td>
<td>Mean ± SD</td>
<td>p-value</td>
</tr>
<tr>
<td>---------</td>
<td>-----------</td>
<td>-----------</td>
<td>---------</td>
</tr>
<tr>
<td>1</td>
<td>1.50 ± 1.87</td>
<td>1.50 ± 1.64</td>
<td>1.000</td>
</tr>
<tr>
<td>2</td>
<td>1.33 ± 1.03</td>
<td>2.50 ± 1.38</td>
<td>0.239</td>
</tr>
<tr>
<td>3</td>
<td>2.17 ± 1.72</td>
<td>0.83 ± 0.75</td>
<td>0.221</td>
</tr>
<tr>
<td>4</td>
<td>1.67 ± 1.86</td>
<td>1.50 ± 1.76</td>
<td>0.895</td>
</tr>
<tr>
<td>5</td>
<td>4.33 ± 0.82</td>
<td>3.67 ± 1.51</td>
<td>0.444</td>
</tr>
<tr>
<td>6</td>
<td>2.67 ± 1.03</td>
<td>2.50 ± 1.52</td>
<td>0.833</td>
</tr>
<tr>
<td>7</td>
<td>1.67 ± 0.82</td>
<td>2.33 ± 1.75</td>
<td>0.484</td>
</tr>
<tr>
<td>8 (QoL)</td>
<td>4.00 ± 0.63</td>
<td>3.50 ± 0.55</td>
<td>0.076</td>
</tr>
</tbody>
</table>

Variables are presented as mean ± standard deviations.

Group A, patients with LF/HF below 1.7; Group B, patients with LF/HF 1.7 and over 1.7;

IPSS, International Prostate Symptom Score; Qmax, Peak uroflow; LF, low frequency; HF, high frequency; QoL, quality of life.

*P<0.05 at the paired t-test.
IV. DISCUSSION

The overall prevalence of LUTS is high, and it increases with age, as does its severity (Ushijiman S et al, 2006). It is commonly divided into the storage, voiding, and postmicturition symptoms. Histopathologically, it has been linked to the BPH. However, not all cases of LUTS are prostate related, and there is evidence demonstrating a direct link between the benign prostatic enlargement (BPE), bladder outlet obstruction (BOO) and LUTS (Choi JB et al, 2010). The extended underlying pathophysiology leading to LUTS remains unclear, although it is increasingly recognized that the causes of LUTS extend well beyond BPE and BOO (Bushman W., 2009). The multiple pathways leading to the onset and progression of LUTS not only complicate diagnosis but also limit the overall effectiveness and satisfaction of targeted symptom management strategies (McConnell JD et al, 2003). Therefore, treatment efficacy varies between individuals. Hyperactivity of the sympathetic nervous system may evoke LUTS, as shown in several studies about autonomic functions in male patients with LUTS. Previous epidemiological studies have suggested that there might be a relationship between the sympathetic overactivity and LUTS in male patients with BPH. Meigs et al. (Meigs JB et al, 2001) noted that men with symptomatic BPH were also more likely to have characteristics associated with increased sympathetic activation, particularly in those who had heart disease, used β-blockers and lived a sedentary lifestyle.

The HRV is a simple and important tool for studying the autonomic control of the heart and autonomic dysfunction, and it represents one of the most promising markers (Eur Heart J, 1996). We suggest the possibility of ANS imbalance and the use of HRV as a method to evaluate ANS tone. It depends on the effects of sympathetic and vagal activities on the sinus
node, and its variability reflects spontaneous changes in autonomic activity (Choi JB et al, 2005). It has been presumed that the HF and RMSSD are mainly responsive to changes in parasympathetic tone, whereas LF and SDNN are dually influenced by other physiologic inputs as well as cholinergic and adrenergic activities. Efferent vagal activity is a major contributor to the HF component, as is seen in clinical and experimental observations of autonomic maneuvers, such as electrical vagal stimulation, muscarinic receptor blockade and vagotomy (Akselrod S et al, 1981; Pomeranz B et al, 1985, Malliani A et al, 1991). Some authors reported that the interpretation of the LF component remains controversial (Malliani A et al, 1991; Kamath MV et al, 1993; Rimoldi O et al, 1990; Montano N et al, 1994), but others did that it is a marker of the sympathetic modulation when it is particularly expressed in normalized units (Akselrod S et al, 1981).

It has been previously shown that there is an increase in the sympathetic tone in patients with LUTS and a greater increase in it in those with voiding symptom. According to Oh et al. (Oh DG et al, 2013), however, the severity of storage symptom was greater in patients with sympathetic hypoactivity, thus presenting with frequency, as compared with those with sympathetic hyperactivity.

We conducted the current study to examine the difference in the treatment efficacy between patients with LUTS with sympathetic hyperactivity and those with sympathetic hypoactivity. The degree of the treatment efficacy is relatively lower in male patients with LUTS who had sympathetic hyperactivity as compared with those with sympathetic hypoactivity. Alfuzosin is a selective α-blocker but it does not have selectivity for the α1-receptor subtypes. This explains the reason to ignore the difference of sympathetic activity. It can therefore be inferred that there would be different outcomes if there are any chances that
α1a-selective blockers, such as tamsulosin or silodosin, are used. This deserves further studies.

There are several limitations of the current study are as follows:

1. We enrolled a small number of patients in the current study. It was a pilot study to
determine the role of autonomic activity in the treatment of patients with LUTS. This deserves further large-scale studies.

2. The LUTS are not specific but subject to change depending on the factors that are not associated with prostatic conditions such as diet, fluid intake, alcohol intake, anticholinergic effects of commonly used over-the-counter medications, smoking and even mood or physical activity (Boyle P et al, 2003; Fowke JH et al, 2013; Harte CB et al, 2013). In the current study, we attempted to control such effects by encouraging the patients not to consume anything that may affect the activity of the ANS prior to the measurement of the HRV.

3. We enrolled relatively younger subjects as compared with a general group of patients with LUTS. The age difference might have been due to exclusion criteria. We excluded men with underlying diseases that may affect the activity of the ANS, such as diabetes and hypertension. Such diseases commonly show a lower prevalence in younger men who commonly take less medications that may affect the activity of the ANS. Many patients with LUTS who do not respond to current medications or surgical treatments have a poor quality of life. Our results suggest that ANS disturbances, especially sympathetic hyperactivity, may be involved in the progression of diseases in men with LUTS.
V. CONCLUSIONS

In conclusion, our results indicate that the treatment efficacy was lower in patients with sympathetic hyperactivity as compared with those with sympathetic hypoactivity. Thus, our results will provide a basis for further studies to clarify causes of LUTS in a clinical setting.

REFERENCES

syndrome. *Neurourol Urodyn* 30:1467-72, 2011


- 국문요약 -

하부 요로 증상 환자에서 교감 신경 활성도와 치료 효과와의 상관성

아주대학교 대학원 의학과
장 현 익
(지도교수 : 최종보)
목적: 이번 연구에서 하부 요로 증상을 겪는 남자 환자들에게서 교감신경 활성도에 따른 치료 효과 차이를 알아보고자 하였다.

대상 및 방법: 단일 센터, 후향적 연구로 진행되었으며, 40에서 70세 사이의 국제 전립선 증상 점수 (International Prostate Symptom Score, IPSS)는 8점 이상인 총 66명의 하부 요로 증상을 보이는 남자 환자들을 대상으로 하였다. 대상 환자군은 지난 3개월동안 alfuzosin XL을 복용했으며, 심박변이도 (heart rate variability, HRV)를 치료 전 및 치료 후 측정하였다. 추가로, 39명의 건강증진센터에서 주기적으로 검진을 받은 건강한 지원자를 선발하였다. 이들 나이는 40세에서 70세 사이였으며 국제 전립선 증상 점수는 8점 미만이었다. 하부 요로 증상을 가진 환자들은 그룹 A 및 B로 나누었는데, low frequency/high frequency (LF/HF) ratio 값을 1.7을 기준으로 하였다. 이 값은 건강한 지원자들의 LF/HF ratio 값의 평균이었다. Alfuzosin XL 복용 3개월 후, 두 그룹 간에 국제 전립선 증상 점수 및 최대 요속의 결과 값을 비교하였다.

결과: Alfuzosin XL 투약 3개월 이후에도 심박변이도를 측정한 환자수는 그룹 A에서는 38명 중 23명이었고, 그룹 B에서는 28명 중 17명이었다. Alfuzosin XL 3개월 투약 후, 전체 국제 전립선 증상 점수 및 문항 2번과 문항 5번의 점수가 그룹 B에 비해 그룹 A에서 현저하게 낮게 나타났다. 이러한 결과는 그룹 B에서는 나타나지 않았다. 게다가, 최대 요속이나 국제 전립선 증상 점수 중 저장 증상과 관련된 항목 점수 등 다른 계수들에서는 두 그룹 간에 차이점을 보이지 않았다.

결과: 연구 결과에 따르면 교감 신경계 과활성군이 저활성군에 비해서 치료 효과가 떨어짐을 알 수 있다. 따라서 본 연구는 하부 요로 증상의 원인 규명에 대한 앞으로의 연구의 근거를 제공할 수 있을 것이다.
핵심어: 자율신경계; 심박수; 하부 요로 증상